Cargando…

Balancing the Risks and Benefits of Long‐Term Antiplatelet Therapies for Cardiovascular Disease: Clinical, Research, and Regulatory Implications

Detalles Bibliográficos
Autores principales:	Alfredsson, Joakim, Roe, Matthew T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392454/ https://www.ncbi.nlm.nih.gov/pubmed/25792126 http://dx.doi.org/10.1161/JAHA.115.001897

Ejemplares similares

Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke
por: Hilkens, Nina A., et al.
Publicado: (2021)

Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease
por: Carreras, Edward T., et al.
Publicado: (2013)

Cardiovascular Safety of Celecoxib on Top of Dual Antiplatelet Therapy
por: Hong, Bum-Kee
Publicado: (2010)

Individualized Antiplatelet Therapy: A Long Way to Go
por: Han, Ya-Ling
Publicado: (2018)

Antiplatelet therapy and the vascular tree
por: Blann, A
Publicado: (2006)

Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS?
por: Brunetti, Natale Daniele, et al.
Publicado: (2019)

Antiplatelet therapy and bladder tumor resection
por: Goel, Apul, et al.
Publicado: (2018)

Precision antiplatelet therapy for the prevention of ischaemic stroke
por: Wang, David
Publicado: (2021)

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019)

Genetic testing in antiplatelet therapy – not effective for perioperative bleeding
por: Kuliczkowski, Wiktor
Publicado: (2017)

Antiplatelet therapy for elderly patients with Acute Coronary Syndromes
por: Savonitto, Stefano, et al.
Publicado: (2018)

Balance deficits in long-term pediatric ALL survivors
por: Varedi, Mitra, et al.
Publicado: (2018)

Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
por: Lee, Kwan Yong, et al.
Publicado: (2022)

Balancing risk and benefit during coronavirus
por: Sehn, Laurie H.
Publicado: (2020)

Gastroprotection during long-term dual antiplatelet therapy: to give or not to give?
por: Sbrana, Francesco, et al.
Publicado: (2021)

Novel aspects of antiplatelet therapy in cardiovascular disease
por: Gremmel, Thomas, et al.
Publicado: (2018)

Antiplatelet therapy following TAVI: time to randomise
por: Delewi, R., et al.
Publicado: (2014)

Gene Therapy in Cardiovascular Research
por: Tosaki, Arpad
Publicado: (2012)

Long-Term Safety and Efficacy of Antiplatelet Therapy in Patients With Cerebral Infarction With Thrombocytopenia
por: Guo, Shijie, et al.
Publicado: (2021)

Long-term antibiotics in COPD: more benefit than harm?
por: Miravitlles, Marc
Publicado: (2013)

Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
por: Jourdi, Georges, et al.
Publicado: (2021)

Antiplatelet Drugs and Endothelial Function
por: Higashi, Yukihito
Publicado: (2016)

Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit
por: Ewer, Michael S, et al.
Publicado: (2016)

Balancing the benefits and harms of radiotherapy post-radical prostatectomy
por: Lamb, Benjamin W., et al.
Publicado: (2018)

Balancing risks and benefits of artificial intelligence in the health sector
por: Goodman, Kenneth, et al.
Publicado: (2020)

Neurosurgical innovation: balancing the risks and benefits of technical novelty
por: Cohen-Gadol, Aaron A.
Publicado: (2019)

Benefit-risk balance of COVID drugs. New prospects
por: Cracowski, Jean-Luc, et al.
Publicado: (2022)

Anticipating the long-term cardiovascular effects of COVID-19
por: Becker, Richard C.
Publicado: (2020)

Antiplatelet therapy in cardiovascular disease: Current status and future directions
por: Passacquale, Gabriella, et al.
Publicado: (2022)

Immature platelet fraction in cardiovascular diagnostics and antiplatelet therapy monitoring
por: Gumiężna, Karolina, et al.
Publicado: (2023)

Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
por: Shen, Ying, et al.
Publicado: (2015)

Dual antiplatelet therapy and newer agents: More efficacy but lets keep the brain safe!!
por: Bhatia, Rohit, et al.
Publicado: (2015)

Surgeon's guide to anticoagulant and antiplatelet medications part two: antiplatelet agents and perioperative management of long-term anticoagulation
por: Yeung, Louise Y Y, et al.
Publicado: (2016)

Balancing research and clinical practice
por: Gupta, Ravi
Publicado: (2017)

Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada
por: Lordkipanidzé, Marie, et al.
Publicado: (2020)

Rho GTPase Signaling in Platelet Regulation and Implication for Antiplatelet Therapies
por: Dandamudi, Akhila, et al.
Publicado: (2023)

Implications of direct oral anticoagulation and antiplatelet therapy in intensive care
por: Willcox, Abbey, et al.
Publicado: (2023)

Long term risk and costs of bleeding in men and women treated with triple antithrombotic therapy–An observational study
por: Holm, Anna, et al.
Publicado: (2021)

Antiplatelet therapy and long-term mortality in patients with myocardial injury after non-cardiac surgery
por: Kim, Jihoon, et al.
Publicado: (2023)

Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: awaiting for evidence
por: Liga, Riccardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0n287a9bme2v15pif45rp9ktjf